Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

A Study Of Poly (ADP-Ribose) Polymerase Inhibitor PF-01367338 In Combination With Several Chemotherapeutic Regimens

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Clovis Oncology, Inc.
ClinicalTrials.gov Identifier:
NCT01009190
First received: November 4, 2009
Last updated: March 8, 2014
Last verified: March 2014
  Purpose

Dose escalation phase 1 study of PARP inhibitor PF-01367338 in combination with chemotherapy in adult patients with advanced solid tumors


Condition Intervention Phase
Advanced Solid Tumors
Drug: PF-01367338
Drug: Carboplatin
Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Parallel Arms Phase 1 Safety, Pharmacokinetic And Pharmacodynamic Study Of The Intravenous Poly (ADP-Ribose) Polymerase (PARP) Inhibitor PF-01367338 (AG-014699) In Combination With Several Chemotherapeutic Regimens In Adult Patients With Advanced Solid Tumor

Resource links provided by NLM:


Further study details as provided by Clovis Oncology, Inc.:

Primary Outcome Measures:
  • Safety and tolerability of escalating doses of PF-01367338 in combination with chemotherapy (as defined by first-cycle DLTs) [ Time Frame: 18 months ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Pharmacokinetics and pharmacodynamics of escalating doses of PF-01367338 in combination with several chemotherapeutic regimens [ Time Frame: 18 months ] [ Designated as safety issue: No ]
  • Determination of F constant for bioavailability of oral PF-01367338 compared to intravenous PF-01367338 [ Time Frame: 18 months ] [ Designated as safety issue: No ]
  • Determination of food effect on oral PF-01367338 pharmacokinetics [ Time Frame: 18 month ] [ Designated as safety issue: No ]
  • Determination of effect of PF-013567338 administration on QTc prolongation test [ Time Frame: 18 months ] [ Designated as safety issue: No ]
  • Characterization of PF-01367338 metabolite profile [ Time Frame: 18 months ] [ Designated as safety issue: No ]

Estimated Enrollment: 60
Study Start Date: February 2010
Estimated Study Completion Date: April 2014
Estimated Primary Completion Date: March 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: ARM A
Carboplatin plus PF-01367338
Drug: PF-01367338
Increasing doses of single lead-in (Day -10) intravenous and daily oral PF-01367338 administered from Day 1 to Day 14 every 3-week cycle
Drug: Carboplatin
Standard doses of intravenous Carboplatin administered every 3 weeks
Experimental: ARM A EXPANSION
Carboplatin plus PF-01367338
Drug: PF-01367338
RP2 doses of oral PF-01367338 administered daily from Day 1 to Day 14 every 3-week cycle
Drug: Carboplatin
Standard doses of intravenous Carboplatin administered every 3 weeks

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients with histologically confirmed solid tumors, Eastern Cooperative Oncology Group (ECOG) 0 or 1
  • Patients with acceptable renal, hepatic, and bone marrow function

Exclusion Criteria:

  • Symptomatic and/or unstable brain metastases,
  • Any cancer treatment within 4 weeks from study entry
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01009190

Locations
United Kingdom
Churchill Hospital
Oxford, Oxfordshire, United Kingdom, OX3 7LJ
Royal Marsden Hospital
Sutton, Surrey, United Kingdom, SM2 5PT
Belfast City Hospital
Belfast, United Kingdom, BT9 7AB
Beatson West of Scotland Cancer Centre
Glasgow, United Kingdom, G12 0YN
Kings College London
London, United Kingdom, SE1 9RT
Sir Bobby Robson Cancer Trials Research Centre
Newcastle Upon Tyne, United Kingdom, NE7 7DN
Sponsors and Collaborators
Clovis Oncology, Inc.
  More Information

No publications provided

Responsible Party: Clovis Oncology, Inc.
ClinicalTrials.gov Identifier: NCT01009190     History of Changes
Other Study ID Numbers: CO-338-1014
Study First Received: November 4, 2009
Last Updated: March 8, 2014
Health Authority: United States: Food and Drug Administration

Keywords provided by Clovis Oncology, Inc.:
Dose finding PARPi Chemotherapy

Additional relevant MeSH terms:
Carboplatin
Antineoplastic Agents
Pharmacologic Actions
Therapeutic Uses

ClinicalTrials.gov processed this record on November 20, 2014